Zydus Lifesciences Disrupts Respiratory Care with India’s First Affordable Drug-Free Device ‘PepairTM’ at ₹990

Market snapshot: Zydus Lifesciences has expanded its medical technology footprint by launching PepairTM, a first-of-its-kind drug-free handheld device in India. Priced at ₹990, the device targets the high-burden respiratory segment, specifically patients suffering from Chronic Obstructive Pulmonary Disease (COPD), Asthma, and Bronchiectasis. This launch coincides with Zydus's strategic shift toward diversifying its portfolio into non-pharmacological interventions and high-value MedTech solutions.

Summary: Zydus Lifesciences launches PepairTM, a drug-free respiratory device for COPD and Asthma, priced affordably at ₹990 to improve lung health without medication dependency.

Key Takeaways

• First-to-market affordable drug-free handheld respiratory device in India.
• Targeting a massive addressable market of COPD and Asthma patients needing non-invasive therapy.
• Strategic pricing at ₹990 enhances accessibility and penetration in the Indian branded formulations and device segment.

SAHI Perspective

The launch of PepairTM is a calculated move to capture a share of the ancillary respiratory market. While Zydus's core strength remains generics and biosimilars, this MedTech entry aligns with its recent 14% YoY growth in India's branded formulation business reported in Q3 FY26. By offering a low-cost, drug-free alternative, Zydus is positioning itself as a holistic healthcare provider, potentially improving patient stickiness in its chronic therapy portfolio.

Closing Insight

PepairTM represents Zydus’s commitment to patient-centric innovation at an accessible price point. This diversification into MedTech, supported by robust cash flows from its US generics business, strengthens its defensive position in the Indian market.

High Performance Trading with SAHI.

Synthetically modified: AI-generated content by Sahi Live News Engine.